MDinteractive is an approved CMS Qualified Registry for 2021.

Miss our APM Performance Pathway Webinar? Watch it now!

MDinteractive accepting customers for Primary Care First program.

Join us for our 2021 MIPS Overview Webinar on Wednesday, June 16 at 1 p.m. EST. Register here.

2021 MIPS IA_PSPA_31: Patient Medication Risk Education

Activity ID

IA_PSPA_31

Activity Weighting

High

Subcategory Name

Patient Safety and Practice Assessment

Activity Description

In order to receive credit for this activity, MIPS eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. Education must be completed for at least 75% of qualifying patients and occur: (1) at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or (2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

Objective

Educate patients regarding the risks of concurrent opioid and benzodiazepine use, thus reducing their risk of overdose.

Suggested Documentation

Evidence of both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use provided to patients who are prescribed both benzodiazepines and opioids. Include both of the following elements:

1) Examples of education provided – Copies of written education (e.g., pamphlets, patient portal screenshot) and verbal education (e.g., scripts/descriptions of what must be said) provided; AND
2) Education provided to patients co-prescribed – Education must be completed for at least 75% of qualifying patients and occur a) at the time of initial co-prescribing and again following greater than 6 months of co-prescribing of benzodiazepines and opioids; or b) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

Register with MDinteractive